

Adolescent Immunisation

Age	Brand	Disease/Antigen	Notes
Year 7 students (ages 12-13)	Gardasil®9 Boostrix® or Adacel®	Human papillomavirus (HPV) Diphtheria, tetanus, pertussis (dTpa)	Gardasil®9: Single dose recommended. Immunocompromised people require a 3-dose schedule given at 0, 2 and 6 months. Refer to the Australian Immunisation Handbook-HPV chapter
Year 10 students (ages 14-16)	MenQuadfi®	Meningococcal ACWY (MenACWY)	Adolescents who have received a MenACWY vaccine in the past should still receive a dose after they turn 14 years of age.

Adult Immunisation

Age	Brand	Disease/Antigen	Notes
18 years and over	Age-appropriate COVID-19 vaccine	COVID-19	Adults aged over 18 without severe immunocompromise who have not previously received a COVID-19 vaccine are recommended a single primary dose. All adults aged over 75 years are recommended further doses every 6 months. Adults aged 65 -74 years are recommended further doses every 12 months and can consider every 6 months based on a risk-benefit assessment. Adults aged 18-64 without severe immunocompromise can consider further doses every 12 months. See the Australian Immunisation Handbook-COVID-19 chapter for further information on COVID-19 vaccination recommendations.
Aboriginal people 50 years and over	Prevenar 13® and Pneumovax 23® Shingrix®	Pneumococcal (13vPCV and 23vPPV) Shingles/herpes zoster (VZV)	Pneumococcal: Administer a dose of 13vPCV, followed 2-12 months later by a first dose of 23vPPV, then a second dose of 23vPPV at least 5 years later. Shingrix®: Two dose course given 2-6 months apart (or 1-2 months apart if immunocompromised).
65 years and over	Fluad Quad® Shingrix®	Influenza Shingles/herpes zoster (VZV)	Influenza: Administer annually. Shingrix®: Two dose course, given 2-6 months apart (or 1-2 months apart if immunocompromised). Does not need to be repeated if the recommended interval between doses is exceeded.
70 years and over	Prevenar 13®	Pneumococcal (13vPCV)	A single dose is recommended at age 70. Aboriginal people who have already received a dose of 13vPCV from 50 years do not require another dose.
Aboriginal people of all ages	Influenza, age-appropriate brand	Influenza	Administer annually

Immunisation in Pregnancy

Stage	Brand	Disease/Antigen	Notes
20-32 weeks gestation	Boostrix® or Adacel®	Diphtheria, tetanus, pertussis (dTpa)	Single dose recommended in each pregnancy, ideally at 20–32 weeks gestation, but may be given up until delivery. Can be co-administered with other maternal vaccines.
28-36 weeks gestation	Abrysvo®	Respiratory syncytial virus (RSV)	Single dose recommended in pregnancy at 28-36 weeks gestation. Can be co-administered with other maternal vaccines.
Any stage of pregnancy	Influenza, age-appropriate brand	Influenza	A single dose is recommended in each pregnancy, at any stage of pregnancy. If a pregnancy spans two influenza seasons, a vaccine may be given in each season. Can be co-administered with other maternal vaccines.

Additional Immunisation for people with medical risk conditions

Age	Brand	Disease/Antigen	Notes
All ages	Nimenrix® Bexsero®	Meningococcal ACWY (MenACWY) Meningococcal B (Men B)	For those with specified medical risk conditions that increase their risk of meningococcal disease, including asplenia and haematopoietic stem cell transplant. Number of doses needed depends on age. Refer to the Australian Immunisation Handbook-Meningococcal chapter
Over 6 months	Age-appropriate brand	Influenza	For all those over 6 months of age with specific medical conditions that increase their risk of complications from influenza. Administer annually.
Over 6 months	Age appropriate COVID-19 vaccine	COVID-19	COVID-19 vaccination recommendations vary according to age and medical risk conditions. Refer to the Australian Immunisation Handbook-COVID-19 chapter for further information.
Over 12 months	Prevenar 13® and Pneumovax 23®	Pneumococcal (13vPCV and 23vPPV)	For people over 12 months of age with newly identified risk conditions administer a single dose of 13vPCV at diagnosis followed by a first dose of 23vPPV 12 months later. Give a second dose of 23vPPV at least 5 years after the first. For infants under 12 months of age, refer to the <i>Childhood Immunisation Schedule Tasmania</i> .
Over 5 years	Act-Hib®	<i>Haemophilus influenzae</i> type b (Hib)	For those over 5 years with asplenia or hyposplenia a single dose is required if that person was not vaccinated in infancy or was incompletely vaccinated (note that all children aged <5 years are recommended to complete Hib vaccination regardless of asplenia or hyposplenia).
Over 18 years	Shingrix®	Shingles/herpes zoster (VZV)	For those over 18 years of age with specified medical risk conditions that increase their risk of zoster. Give 1-2 months apart in people who are immunocompromised.

State funded programs

Program	Brand	Disease/Antigen	Notes
Hepatitis B for high-risk groups	Engerix B®	Hepatitis B (HBV)	Standard 3-dose schedule for those at increased risk of acquiring hepatitis B. For eligibility criteria see Hepatitis B vaccine for high-risk groups on the Tasmanian Department of Health website.
Measles	M-M-R II®	Measles, mumps, rubella (MMR)	People born during or after 1966 without documented evidence of two measles containing vaccines or serological evidence of immunity. Infants aged 6-12 months travelling overseas (will need repeating if given prior to 11 months of age).
Mpox	Jynneos®	Mpox	For those aged over 16 years who meet the eligibility criteria give 2 doses at least 28 days apart before exposure to mpox. See Mpox on the Tasmanian Department of Health website. Contact Public Health Services for post-exposure vaccination advice.

Additional Considerations:

- People less than 20 years of age who have a Medicare card, refugees and humanitarian entrants of all ages are eligible for free catch-up vaccines.
- Gardasil®9 vaccine is funded up to and including 25 years of age.

For further advice contact the Tasmanian Department of Health by email immunisation@health.tas.gov.au or phone 1800 671 738

We use the word "Aboriginal" to describe all Aboriginal and Torres Strait Islander people in Tasmania, in recognition that Aboriginal people are the original inhabitants and traditional owners of Lutruwita/Tasmania. This schedule has been adapted from the National Immunisation Program Schedule with permission from the Australian Government Department of Health and Aged Care.